Pneumococcal Immunization

Vaccines
3
Pipeline Programs
1
Companies
7
Clinical Trials
2 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
1
0
1
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Vaccine
3100%

Competitive Landscape

1 companies ranked by most advanced pipeline stage

Sanofi
SanofiPARIS, France
3 programs
1
1
1
PCV21 vaccinePhase 3Vaccine5 trials
Pneumococcal Conjugate Vaccine - formulation 1-SP0202-IIbPhase 2Vaccine1 trial
Pneumococcal Conjugate VaccinePhase 1Vaccine1 trial
Active Trials
NCT06698198Completed175Est. Sep 2019
NCT04583618Completed750Est. Jan 2022
NCT07348692Recruiting896Est. Jan 2028
+4 more trials

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
SanofiPCV21 vaccine
SanofiPCV21 vaccine
SanofiPCV21 vaccine
SanofiPCV21 vaccine
SanofiPCV21 vaccine
SanofiPneumococcal Conjugate Vaccine - formulation 1-SP0202-IIb
SanofiPneumococcal Conjugate Vaccine

Clinical Trials (7)

Total enrollment: 7,527 patients across 7 trials

NCT07348692SanofiPCV21 vaccine

Lot-to-lot Consistency Study of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From 2 Months of Age

Start: Jan 2026Est. completion: Jan 2028896 patients
Phase 3Recruiting
NCT06975878SanofiPCV21 vaccine

Study of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age

Start: May 2025Est. completion: Aug 20271,092 patients
Phase 3Active Not Recruiting
NCT06824181SanofiPCV21 vaccine

Study of Mixed Vaccination Schedules With a 21-valent Pneumococcal Conjugate Vaccine and a 20-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age

Start: Feb 2025Est. completion: Sep 2027580 patients
Phase 3Active Not Recruiting
NCT06824194SanofiPCV21 vaccine

Study of the Safety of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age

Start: Feb 2025Est. completion: May 20272,320 patients
Phase 3Recruiting
NCT06736041SanofiPCV21 vaccine

Study of a 4-Dose Regimen of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age

Start: Dec 2024Est. completion: May 20271,714 patients
Phase 3Active Not Recruiting
NCT04583618SanofiPneumococcal Conjugate Vaccine - formulation 1-SP0202-IIb

Study of a Pneumococcal Conjugate Vaccine in Adults Aged 50 to 84 Years.

Start: Oct 2020Est. completion: Jan 2022750 patients
Phase 2Completed
NCT06698198SanofiPneumococcal Conjugate Vaccine

Safety and Immunogenicity of a Pneumococcal Conjugate Vaccine Candidate in Healthy Adults (19-49 Years)

Start: Dec 2018Est. completion: Sep 2019175 patients
Phase 1Completed

Related Jobs in Vaccines

Senior Associate Scientist- Formulations

Pfizer
United States - Massachusetts - Andover
20h ago
$69K - $114K/yr

Sr. Associate Scientist, Upstream Process Development

Pfizer
United States - Massachusetts - Andover
Yesterday
$69K - $114K/yr

Professional Health Representative

Pfizer
Qatar - Doha
Yesterday

Renal / Rare Regional Director – West

Novartis
Field Sales (USA)
2d ago
$204K - $380K/yr

Associate Director, Commercial Operations (Trade Operations)

Moderna
Princeton, New Jersey
2d ago
$143K - $257K/yr

Associate Director, Commercial Operations (Trade Operations)

Moderna
USA - New Jersey - Princeton - 5 Vaughn Drive
2d ago
$143K - $257K/yr

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 late-stage (Phase 3) programs — potential near-term approvals
2 actively recruiting trials targeting 7,527 patients
1 companies competing in this space

Related Indications

Pneumococcal Vaccines(11)Meningococcal Vaccine(5)Vaccination(4)Vaccine Hesitancy(4)